"Profit Alert" RemeGen's revenue increased by 89%, forecasting an annual profit of over 700 million RMB

RemeGen (09995.HK) issued a profit warning, expecting a net profit of approximately RMB 716 million for the fiscal year 2025, compared to a loss of RMB 1.468 billion in the previous year. The turnaround from loss to profit is mainly due to the rapid growth in domestic sales revenue of core products Tislelizumab and Vadastuximab, which have become the core growth engines of the performance; at the same time, the company successfully reached a significant cooperation, granting Vor Biopharma Inc. the development and commercialization rights for Tislelizumab, resulting in a substantial increase in technology licensing revenue. In addition, through management optimization and iterative production processes, the company has reduced unit production costs and improved product gross margins. The total operating revenue for the year is approximately RMB 3.25 billion, an increase of 89%